The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity.

Sponsor
Second Xiangya Hospital of Central South University
Study ID
NCT05005741
Phase
PHASE4
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Beinaglutide — DRUG
    Patients received beinaglutide subcutaneously three times a day for 16 weeks, the dose of beinaglutide escalate from 0.06mg to 0.2mg per 3-7 days according to subject's specific situation.
  • Dulaglutide — DRUG
    Patients received 1.5mg Dulaglutide subcutaneously once-weekly for 16 weeks.

Study Details

This study is a multi-center, open label, randomized controlled trial that main purpose of this study is to evaluate the differences of glucose control and weight loss between Beinaglutide and Dulaglutide in type 2 diabetes with overweight or or Obesity.

Key Dates

Start date
May 1, 2021
Status verified
Mar 2023
Primary completion
Dec 31, 2023
Completion
Dec 31, 2023

Study Design

Enrollment
120 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Beinaglutide
  • Active Comparator: Dulaglutide

Primary Outcome Measure

haemoglobin A1c(HbA1c) [ Time Frame: From baseline to 16 week. ]

Central Contacts

Related Studies